Results 211 to 220 of about 218,083 (286)

Valorization of paper sludge for bioethanol and biogas production

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study evaluated the physicochemical properties and bioenergy potential of three distinct paper sludges: virgin pulp sludge (VP‐PS), corrugated cardboard sludge (CR‐PS), and tissue and printing paper sludge (TPR‐PS). From the experimental runs, VP‐PS exhibited the highest ethanol yield (46.8 ± 3.7 g L−1, 87.4% conversion), which can be ...
Anné Williams, John Edison Sempiira, Lalitha Devi Gottumukkala, Sampson Mamphweli, Eugene Van Rensburg, Johann Görgens   +5 more
wiley   +1 more source

The financial impact of NIH's indirect cost cap on higher education research. [PDF]

Health Aff Sch
Ford EW, Huerta TR.
europepmc   +1 more source

Market potential of biobased chemicals: a qualitative network analysis of adoption dynamics in South Africa’s bioeconomy

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The premise of a bioeconomy is the replacement of nonrenewable and unsustainable fossil‐derived resources and associated technologies with more sustainable alternatives. The adoption of biobased chemicals contributes toward the growth of a bioeconomy and is dependent on market and industry requirements.
Prisha Mandree, George Alex Thopil, Santosh Ramchuran   +2 more
wiley   +1 more source

Perspectives of California Legislators on Institutional Barriers and Facilitators to Non-Partisan Research Evidence Use in State Health Policymaking. [PDF]

J Gen Intern Med
Ashtari N, Abbasi J, Barnert E.
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers

British Journal of Clinical Pharmacology, EarlyView.
Aims In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated
Alexandre O. Gérard, Diane Merino, Marc Labriffe, Fanny Rocher, Delphine Viard, Laurence Zemori, Thibaud Lavrut, Erik M. Donker, Joost D. Piët, Jean‐Paul Fournier, Milou‐Daniel Drici, Alexandre Destere   +11 more
wiley   +1 more source

Defining Death Anew: Reexamining the Twentieth-Century Brain Death Debates and the Uniform Determination of Death Act. [PDF]

Hastings Cent Rep
Clinton AE.
europepmc   +1 more source

Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk‐proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024

British Journal of Clinical Pharmacology, EarlyView.
Aims The Medicines and Healthcare products Regulatory Agency (MHRA) introduced a risk‐proportionate approach to assess clinical trial applications for authorisation in August 2023. This study evaluates the impact of this approach on the timelines for reviewing proposals.
Andrea Manfrin, Kingyin Lee, Crina Cacou, James Pound, Anthony Harnden, June Raine, Munir Pirmohamed   +6 more
wiley   +1 more source

Diffusion and division: A spatial analysis of surrogacy policy determinants in the United States. [PDF]

SSM Popul Health
Gao J, Idris MA, Gallegos GA, Griffin BC, Munroe SV, Windett JH.   +5 more
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source